Drugs / SARS-CoV-2 RBD subunit recombinant protein
SARS-CoV-2 RBD subunit recombinant protein
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05525208 | Sep 2022 → Jul 2023 | COVID-19 | PT Bio Farma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 RBD subunit recombinant protein | “SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma” NCT05525208 ↗ |
| Modality | Vaccine | “SARS-CoV-2 subunit protein recombinant vaccine” NCT05525208 ↗ |